1. Home
  2. BMEA vs CPBI Comparison

BMEA vs CPBI Comparison

Compare BMEA & CPBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$0.60

Market Cap

92.1M

Sector

Health Care

ML Signal

HOLD

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

HOLD

Current Price

$20.75

Market Cap

83.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
CPBI
Founded
2017
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.1M
83.2M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
BMEA
CPBI
Price
$0.60
$20.75
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $6.57
N/A
AVG Volume (30 Days)
★ 2.2M
3.6K
Earning Date
11-03-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.19
9.38
EPS
N/A
★ 0.39
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$53.21
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$15.56
52 Week High
$2.24
$21.83

Technical Indicators

Market Signals
Indicator
BMEA
CPBI
Relative Strength Index (RSI) 22.67 57.09
Support Level N/A $19.74
Resistance Level $1.47 $21.67
Average True Range (ATR) 0.11 0.33
MACD -0.06 0.11
Stochastic Oscillator 2.92 94.97

Price Performance

Historical Comparison
BMEA
CPBI

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.

Share on Social Networks: